TPG GP A, LLC, James G. Coulter, and Jon Winkelried filed a joint Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 4,761,050 shares of Abeona Therapeutics Inc. common stock as of November 6, 2026.
Key Highlights
- Three reporting persons: TPG GP A, LLC (Delaware), James G. Coulter, and Jon Winkelried filed jointly under an Agreement of Joint Filing.
- Aggregate beneficial ownership: Each reporting person is attributed 4,761,050 shares of Abeona Therapeutics common stock, representing 7.0% of the class.
- No sole voting or dispositive power: All 4,761,050 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
- Direct holders: TPG LSI Rise Ellodi, L.P. directly holds 266,667 shares; Ellodi Pharmaceuticals, L.P. directly holds 4,494,383 shares.
- Share count basis: The 7.0% figure assumes 68,041,223 total shares outstanding, comprising 57,146,840 shares reported as of November 5, 2026, plus 4,494,383 shares issued under an Asset Purchase Agreement dated November 6, 2026, plus 6,400,000 shares issued in a private placement on November 10, 2026.
- Beneficial ownership disclaimed: According to the filing, Messrs. Coulter and Winkelried "disclaim beneficial ownership of such shares of Common Stock held by the Holders except to the extent of their pecuniary interest therein."
TPG-Affiliated Entities Accumulate Abeona Therapeutics Shares Through Asset Purchase and Private Placement
The Schedule 13G filed November 16, 2026 covers Abeona Therapeutics Inc. (NASDAQ:ABEO) common stock, $0.01 par value, CUSIP 00289Y206. The triggering date of the event requiring the filing is listed as November 6, 2026. The three reporting persons - TPG GP A, LLC, James G. Coulter, and Jon Winkelried - filed jointly pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, with their principal business address listed as c/o TPG Inc., 301 Commerce Street, Suite 3300, Fort Worth, Texas 76102.
According to the filing, TPG GP A, LLC exercises direct or indirect control over a chain of entities ultimately resulting in two direct holders of Abeona common stock: TPG LSI Rise Ellodi, L.P., holding 266,667 shares, and Ellodi Pharmaceuticals, L.P., holding 4,494,383 shares. The filing states that TPG GP A is controlled by entities owned by Messrs. Coulter and Winkelried, which is the basis for attributing the same 4,761,050-share aggregate beneficial ownership figure to each of the three reporting persons individually. All beneficial ownership is reported as shared; no reporting person claims sole voting or dispositive power over any of the shares.
The percentage calculation disclosed in the filing rests on a total share count of 68,041,223. That figure combines the 57,146,840 shares outstanding as of November 5, 2026, as reported in Abeona's Form 10-Q filed November 9, 2026, with 4,494,383 shares issued in connection with an Asset Purchase Agreement entered into on November 6, 2026, and 6,400,000 shares issued in a private placement completed on November 10, 2026. Issuer headquarters are listed as 6555 Carnegie Avenue, 4th Floor, Cleveland, OH 44103.
What Was Disclosed
TPG GP A, LLC, James G. Coulter, and Jon Winkelried jointly reported beneficial ownership of 4,761,050 shares, or 7.0%, of Abeona Therapeutics Inc. common stock via a Schedule 13G, with the event date of November 6, 2026 and filing date of November 16, 2026.




Please wait processing your request...